Fast Five Quiz: Test Your Knowledge of Systemic Treatment for Metastatic Breast Cancer

Winston W. Tan, MD


January 25, 2022

NCCN guidelines recommend endocrine therapy alone or in combination with targeted agents for patients with recurrent metastatic HR-positive, HER2-negative breast cancer, unless visceral crises are present. Chemotherapy should be offered to patients with rapidly progressive visceral disease or with a risk for or evidence of end-organ dysfunction or significant disease-related symptoms.

Many women will benefit from sequential use of endocrine therapies at disease progression, although the optimal sequencing of agents is not yet known.

Immunotherapy with atezolizumab in combination with paclitaxel may be considered for tumors that are HR-negative and HER2-negative.

Learn more about metastatic or recurrent breast cancer treatment protocols.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.